Ask The Board

1. What Happens If We Have A Bunch Of COVID-19 Therapeutic And Vaccine Development Failures? Could Biopharma Be The Next Dot-Com Bubble To Burst In 2021? 1/4/2021

   See the answer from Thomas Wiggans, the founder, chairman, and CEO of Dermira.

2. What COVID-19-Induced Trends Impacting Your Company’s Operations Do You Anticipate Continuing Well Beyond The End Of The Current Pandemic? 1/4/2021

   See the answer from Jim Scibetta, CEO of Maverick Therapeutics.

3. Could The Pandemic Be Just What The Doctor Ordered For Bringing More R&D Minds To Major Biopharma Hubs (e.g., Boston, San Fran)? 1/4/2021

   See the answer from Carol Nacy, PH.D., CEO of Sequella, Inc., a private company that develops new anti-infective drugs.

4. What — If Any — “Silver Linings” Have You Observed Take Place At Your Company Resulting From The Chaos Caused By COVID-19? 10/30/2020

   See the answer from Tom DiLenge, president, advocacy, law & public policy division for the Biotechnology Innovation Organization (BIO).

5. What Was Your Biggest Business Learning From The First Half Of 2020 And Why? 10/30/2020

   See the answer from Liz Bywater, Ph.D., speaker and author of Slow Down to Speed Up! who advises executives at some of the world’s most successful companies.

6. What Is Your Biggest Concern Regarding Biopharma’s Reputation With The American People If We Do Not Have A COVID-19 Vaccine By The End Of 2020? 10/30/2020

   See the answer from Mitchell Katz, Ph.D., VP of development operations at Ferring Pharmaceuticals.

7. What Is Your Biggest Concern Regarding The Biopharma Industry’s Reputation With The American People If We Don’t Have A COVID-19 Vaccine By The End Of This Year? 10/1/2020

   See the answer from Francois Nader, chairman of Acceleron Pharma.

8. What’s Your Perspective On The Rise Around Virtual Pitching To Investors, And What Will Be Its Impact On Annual Investor Meetings Like The Biotech Showcase And JPM In 2021? 10/1/2020

   See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital.

9. What — If Any — Silver Linings Have You Observed Taking Place At Your Company Resulting From The Chaos Caused By COVID-19? 10/1/2020

   See the answer from Joe Ferra, CFO of Syros Pharmaceuticals.

10. What Additional Protocols Have You Observed Being Implemented To Protect Biopharma Manufacturing Employees, And What Impact Do You Anticipate On The Bottom Line From These Added Costs? 9/1/2020

    See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.